Friedman is excited to announce the stock opening of our client, Adial Pharmaceuticals. On Tuesday, September 4th, Adial received their initial public offering (IPO) and listing on the Nasdaq Stock Market. Friedman served as Adial’s initial auditors when the company first decided to go public.
Adial is a pharmaceutical company that is focused on the development of treatments for those suffering from addiction and Alcohol Use Disorder (AUD). William Stilley, CEO of Adial Pharmaceuticals, spoke at the opening saying, “Alcohol Use Disorder is a devastating disease, which takes an enormous toll on our families, our communities, our country and the economy. As recently reported in The Lancet, alcohol is the number one cause of death among both men and women ages 15 to 49 years.”
Learn more about Adial by visiting the Nasdaq website, here.